

Ref. No: 0239
Date: 07/09/23
Subject: Usage of biologic and biosimilar products

REQUEST

It would be really helpful if you could provide the numbers of patients treated by the Rheumatology Department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia]
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Apremilast [Otezla]
- Baricitinib [Olumiant]
- Bimekizumab [Bimzelx]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Filgotinib [Jyseleca]
- Golimumab [Simponi]
- Guselkumab [Tremfya]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Rituximab [MabThera]
- Rituximab Biosimilars
- Sarilumab [Kevzara]
- Secukinumab [Cosentyx]
- Tocilizumab [Ro Actemra]
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]

RESPONSE

Treatment	No. of Patients
Abatacept [Orencia]	55
Adalimumab [Humira]	50
Adalimumab Biosimilars	308
Apremilast [Otezla]	<5
Baricitinib [Olumiant]	81
Bimekizumab [Bimzelx]	0
Certolizumab [Cimzia]	29
Etanercept [Enbrel]	45
Etanercept Biosimilars	219
Filgotinib [Jyseleca]	20
Golimumab [Simponi]	51
Guselkumab [Tremfya]	0
Infliximab [Remicade]	<5
Infliximab Biosimilars	16

Ixekizumab [Taltz]	<5
Risankizumab [Skyrizi]	0
Rituximab [MabThera]	0
Rituximab Biosimilars	18
Sarilumab [Kevzara]	<5
Secukinumab [Cosentyx]	62
Tocilizumab [Ro Actemra]	41
Tofacitinib [Xeljanz]	36
Upadacitinib [Rinvoq]	14
Ustekinumab [Stelara]	8

Section 40: personal information

We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances Section 40(2) and Section 40(3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle which states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in our view, would be breached by disclosure, and in such circumstances, Section 40 confers an absolute exemption on disclosure.